| scholarly article | Q13442814 |
| P2093 | author name string | Theresa L Whiteside | |
| Edwin K Jackson | |||
| P2860 | cites work | Adenosine receptors: therapeutic aspects for inflammatory and immune diseases | Q24651475 |
| Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3 | Q24672849 | ||
| FOXP3+ regulatory T cells in the human immune system | Q29307487 | ||
| Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival | Q29547865 | ||
| How regulatory T cells work | Q29614262 | ||
| Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression | Q29615344 | ||
| Immunosuppressive networks in the tumour environment and their therapeutic relevance | Q29619244 | ||
| Clinical grade Treg: GMP isolation, improvement of purity by CD127 Depletion, Treg expansion, and Treg cryopreservation | Q33367565 | ||
| Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells | Q33748026 | ||
| Inhibiting the inhibitors: evaluating agents targeting cancer immunosuppression | Q33903025 | ||
| Adenosine and prostaglandin E2 cooperate in the suppression of immune responses mediated by adaptive regulatory T cells | Q34107172 | ||
| Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance | Q34111451 | ||
| Type 1 T regulatory cells. | Q34448429 | ||
| Distinct roles of adenylyl cyclase VII in regulating the immune responses in mice | Q34582255 | ||
| Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: hydrolysis of extracellular ATP and immune suppression. | Q34621389 | ||
| The prognostic value of FoxP3+ tumor-infiltrating lymphocytes in cancer: a critical review of the literature | Q34637571 | ||
| Regulatory T cells negatively affect IL-2 production of effector T cells through CD39/adenosine pathway in HIV infection | Q34711777 | ||
| Recruitment of regulatory T cells is correlated with hypoxia-induced CXCR4 expression, and is associated with poor prognosis in basal-like breast cancers. | Q35559050 | ||
| AMP is an adenosine A1 receptor agonist | Q35773917 | ||
| The chemokine, CXCL12, is an independent predictor of poor survival in ovarian cancer | Q35858991 | ||
| Functional regulatory T cells produced by inhibiting cyclic nucleotide phosphodiesterase type 3 prevent allograft rejection. | Q35875359 | ||
| Functionally distinct subsets of human FOXP3+ Treg cells that phenotypically mirror effector Th cells | Q35995214 | ||
| Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation | Q36367099 | ||
| Drug therapy aimed at adenylyl cyclase to regulate cyclic nucleotide signaling | Q36612183 | ||
| Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. | Q36787548 | ||
| The tumor microenvironment and its role in promoting tumor growth | Q36946019 | ||
| Adenosine production by human B cells and B cell-mediated suppression of activated T cells | Q36983750 | ||
| Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes) | Q37040486 | ||
| Compositions for treatment of cancer and inflammation | Q37090388 | ||
| Inhibition of T cell and natural killer cell function by adenosine and its contribution to immune evasion by tumor cells (Review). | Q37091784 | ||
| Mechanisms of regulatory T-cell suppression - a diverse arsenal for a moving target | Q37111968 | ||
| Is FOXP3 a bona fide marker for human regulatory T cells? | Q37131913 | ||
| Expression of RORγt marks a pathogenic regulatory T cell subset in human colon cancer | Q37146190 | ||
| Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression | Q37245083 | ||
| Indoleamine 2,3-dioxygenase-expressing mature human monocyte-derived dendritic cells expand potent autologous regulatory T cells. | Q37268984 | ||
| Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? | Q37493607 | ||
| Adenylyl cyclases as innovative therapeutic goals. | Q37564706 | ||
| CD4 (+)CD25 (+)Foxp3 (+) regulatory T cells and hematologic malignancies | Q37762036 | ||
| Regulatory T cells in tumor immunity | Q37762224 | ||
| Extracellular adenosine triphosphate and adenosine in cancer. | Q37775889 | ||
| Phenotypical and functional specialization of FOXP3+ regulatory T cells | Q37832385 | ||
| Distinct regulatory CD4+T cell subsets; differences between naïve and antigen specific T regulatory cells | Q37917132 | ||
| Prognostic and predictive impact of intra- and peritumoral immune infiltrates | Q37918676 | ||
| The role of anti-inflammatory drugs in colorectal cancer | Q38047412 | ||
| Foxp3 expression in human cancer cells. | Q38524958 | ||
| Expansion of human T regulatory type 1 cells in the microenvironment of cyclooxygenase 2 overexpressing head and neck squamous cell carcinoma | Q40079450 | ||
| Expansion and characteristics of human T regulatory type 1 cells in co-cultures simulating tumor microenvironment | Q40177099 | ||
| T-regulatory cells shift from a protective anti-inflammatory to a cancer-promoting proinflammatory phenotype in polyposis | Q40909943 | ||
| Receptor desensitization and blockade of the suppressive effects of prostaglandin E2 and adenosine on the cytotoxic activity of human melanoma-infiltrating T lymphocytes | Q41832380 | ||
| T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease | Q41888065 | ||
| Ecto-5'-nucleotidase: Structure function relationships | Q42008606 | ||
| Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets | Q42066000 | ||
| Modulation of tryptophan catabolism by regulatory T cells. | Q44632333 | ||
| Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients | Q46312545 | ||
| GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase. | Q46490849 | ||
| Cooperation of adenosine and prostaglandin E2 (PGE2) in amplification of cAMP-PKA signaling and immunosuppression | Q46713114 | ||
| The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck | Q46920694 | ||
| Distinctive role of CCR7 in migration and functional activity of naive- and effector/memory-like Treg subsets. | Q51975593 | ||
| CCR6 expression defines regulatory effector/memory-like cells within the CD25(+)CD4+ T-cell subset. | Q51995543 | ||
| Regulatory T cells stay on course. | Q52889469 | ||
| Expression of Helios in Peripherally Induced Foxp3+ Regulatory T Cells | Q56888758 | ||
| The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells | Q56902123 | ||
| Clinical Impact of Different Classes of Infiltrating T Cytotoxic and Helper Cells (Th1, Th2, Treg, Th17) in Patients with Colorectal Cancer | Q56932821 | ||
| Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients | Q57220173 | ||
| Quantification of Regulatory T Cells Enables the Identification of High-Risk Breast Cancer Patients and Those at Risk of Late Relapse | Q58211903 | ||
| Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells | Q58234949 | ||
| Regulatory T cells in cancer | Q84073243 | ||
| Expanded subpopulation of FoxP3+ T regulatory cells in renal cell carcinoma co-express Helios, indicating they could be derived from natural but not induced Tregs | Q84099411 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostaglandin E2 | Q416554 |
| P304 | page(s) | 212 | |
| P577 | publication date | 2013-07-25 | |
| P1433 | published in | Frontiers in Immunology | Q27723748 |
| P1476 | title | Adenosine and prostaglandin e2 production by human inducible regulatory T cells in health and disease | |
| P478 | volume | 4 |
| Q38872469 | A Bacterial Artificial Chromosome Reporter System for Expression of the Human FOXP3 Gene in Mouse Regulatory T-Cells |
| Q41983445 | A CD38/CD203a/CD73 ectoenzymatic pathway independent of CD39 drives a novel adenosinergic loop in human T lymphocytes |
| Q38900954 | A2A adenosine receptor antagonists to weaken the hypoxia-HIF-1α driven immunosuppression and improve immunotherapies of cancer |
| Q34487689 | Big opportunities for small molecules in immuno-oncology |
| Q38266807 | Clinical Impact of Regulatory T cells (Treg) in Cancer and HIV. |
| Q38196724 | Ectoenzymes in leukocyte migration and their therapeutic potential |
| Q38809772 | Emerging Opportunities and Challenges in Cancer Immunotherapy. |
| Q33878542 | Extracellular adenosine-mediated modulation of regulatory T cells |
| Q88036813 | FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity |
| Q38650710 | Head and Neck Carcinoma Immunotherapy: Facts and Hopes |
| Q99584371 | Human regulatory T cells (Treg) and their response to cancer |
| Q92361171 | Hypoxia Compromises Anti-Cancer Immune Responses |
| Q38215678 | Immunoregulatory activity of adenosine and its role in human cancer progression |
| Q38220701 | Induced regulatory T cells in inhibitory microenvironments created by cancer |
| Q26770780 | Novel technologies and emerging biomarkers for personalized cancer immunotherapy |
| Q38198735 | Phenotypic alterations, clinical impact and therapeutic potential of regulatory T cells in cancer |
| Q38161416 | Regulatory T cell subsets in human cancer: are they regulating for or against tumor progression? |
| Q53109856 | T-helper and T-regulatory cells modulation in head and neck squamous cell carcinoma. |
| Q39235260 | Targeting adenosine in cancer immunotherapy: a review of recent progress. |
| Q64075706 | The Discovery of Biomarkers in Cancer Immunotherapy |
| Q47755372 | The Dual Role of Treg in Cancer |
| Q58787876 | The Impact of Purinergic System Enzymes on Noncommunicable, Neurological, and Degenerative Diseases |
| Q28241308 | The Multifaceted Roles Neutrophils Play in the Tumor Microenvironment |
| Q37413162 | The critical role of the tumor microenvironment in shaping natural killer cell-mediated anti-tumor immunity. |
| Q27006663 | The role of regulatory T cells in cancer immunology |
| Q26824833 | The two-hit hypothesis for neuroinflammation: role of exogenous ATP in modulating inflammation in the brain |
| Q41889070 | Thymus-Derived, Peripherally Derived, and in vitro-Induced T Regulatory Cells |
| Q36542190 | Tumor-derived exosomes regulate expression of immune function-related genes in human T cell subsets |
Search more.